New Gout Medication Approved in China; Phase III Results Announced for US Cancer Vaccine
New Gout Medication Approved in China; Phase III Results Announced for US Cancer Vaccine On August 20, 2026, China’s National Medical Products Administration (NMPA) approved the Class 1 innovative drug anfilimab injection (subcutaneous injection, brand name Yisaina), developed by Sunland Guojian Pharmaceutical (Shanghai) Co., Ltd. The…
Continue reading...